| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10787-012-0126-8 |
| P953 | full work available at URL | http://link.springer.com/article/10.1007/s10787-012-0126-8/fulltext.html |
| http://link.springer.com/content/pdf/10.1007/s10787-012-0126-8 | ||
| http://link.springer.com/content/pdf/10.1007/s10787-012-0126-8.pdf | ||
| P698 | PubMed publication ID | 22427210 |
| P5875 | ResearchGate publication ID | 221715632 |
| P50 | author | Cecilia M. Shing | Q50947931 |
| Luis Vitetta | Q67471781 | ||
| Jonathan M Peake | Q89698245 | ||
| P2093 | author name string | E. Hayes | |
| C. Shing | |||
| D. Briskey | |||
| P2860 | cites work | Oral probiotic and prevention of Pseudomonas aeruginosa infections: a randomized, double-blind, placebo-controlled pilot study in intensive care unit patients | Q21195017 |
| Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis | Q22251072 | ||
| Probiotics for preventing acute upper respiratory tract infections | Q24234353 | ||
| Probiotics for the prevention of pediatric antibiotic-associated diarrhea | Q24235039 | ||
| Commensal bacteria modulate cullin-dependent signaling via generation of reactive oxygen species | Q24296438 | ||
| The gut flora as a forgotten organ | Q24550824 | ||
| Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial | Q24628564 | ||
| Innate immunity and intestinal microbiota in the development of Type 1 diabetes | Q24647312 | ||
| Protein phosphatase 2A associates with and regulates atypical PKC and the epithelial tight junction complex | Q24673684 | ||
| Mechanisms underlying the resistance to diet-induced obesity in germ-free mice | Q24676006 | ||
| Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial | Q24685494 | ||
| Structural bacterial molecules as potential candidates for an evolution of the classical concept of probiotics | Q26996471 | ||
| Probiotics in Inflammatory Bowel Diseases and Associated Conditions | Q27002496 | ||
| Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation | Q27327276 | ||
| A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome | Q27499182 | ||
| Medicine today | Q27718015 | ||
| VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study | Q39286213 | ||
| Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome | Q39348241 | ||
| A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome | Q39396709 | ||
| Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair | Q40211588 | ||
| Effect of the continuous intake of probiotic-fermented milk containing Lactobacillus casei strain Shirota on fever in a mass outbreak of norovirus gastroenteritis and the faecal microflora in a health service facility for the aged | Q40326901 | ||
| Cutting edge: bacterial modulation of epithelial signaling via changes in neddylation of cullin-1. | Q40370404 | ||
| Lactobacillus casei DN-114 001 inhibits the increase in paracellular permeability of enteropathogenic Escherichia coli-infected T84 cells. | Q40450359 | ||
| Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer | Q40538834 | ||
| Immune responses of specific pathogen-free and gnotobiotic mice to antigens of indigenous and nonindigenous microorganisms | Q40880257 | ||
| The response of the lymphatic tissue to the microbial flora. Studies on germfree mice | Q42414281 | ||
| Oxidative stress enhances IL-8 and inhibits CCL20 production from intestinal epithelial cells in response to bacterial flagellin | Q42994233 | ||
| Beneficial effects of fructo-oligosaccharides supplementation on fecal bifidobacteria and index of peroxidation status in constipated nursing-home residents--a placebo-controlled, diet-controlled trial | Q43318307 | ||
| Yoghurt containing galacto-oligosaccharides, prunes and linseed reduces the severity of mild constipation in elderly subjects | Q43344253 | ||
| Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial | Q43363077 | ||
| Mucosal flora in inflammatory bowel disease | Q43503928 | ||
| Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis | Q43988863 | ||
| Decrease in frequency of liquid stool in enterally fed critically ill patients given the multispecies probiotic VSL#3: a pilot trial | Q44447547 | ||
| Ciprofloxacin resistance in Neisseria gonorrhoeae in England and Wales in 2002. | Q44447887 | ||
| Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. | Q45200144 | ||
| Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome | Q46451586 | ||
| Prevention of recurrence with epirubicin and lactobacillus casei after transurethral resection of bladder cancer | Q46852747 | ||
| Neddylation and deneddylation regulate Cul1 and Cul3 protein accumulation. | Q47070899 | ||
| Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease | Q47220054 | ||
| Association Between the Use of Antibiotics and New Diagnoses of Crohn's Disease and Ulcerative Colitis | Q47249731 | ||
| A Randomized, Double-blind, Placebo-controlled Pilot Study of Lactobacillus reuteri ATCC 55730 for the Prevention of Antibiotic-associated Diarrhea in Hospitalized Adults | Q51466665 | ||
| Toll-dependent control mechanisms of CD4 T cell activation | Q51996404 | ||
| Assessment of the safety, tolerance, and protective effect against diarrhea of infant formulas containing mixtures of probiotics or probiotics and prebiotics in a randomized controlled trial | Q53728712 | ||
| Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. | Q54486654 | ||
| The assessment of faecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique. | Q54690616 | ||
| Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. | Q55036595 | ||
| A mixture ofEscherichia coli(DSM 17252) andEnterococcus faecalis(DSM 16440) for treatment of the irritable bowel syndrome - A randomized controlled trial with primary care physicians | Q56883300 | ||
| Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles | Q59880418 | ||
| Probiotics affect the clinical inflammatory parameters of experimental gingivitis in humans | Q61047302 | ||
| Effects of galactooligosaccharide and long-chain fructooligosaccharide supplementation during pregnancy on maternal and neonatal microbiota and immunity--a randomized, double-blind, placebo-controlled study | Q62555665 | ||
| Crohn's disease intestinal CD4+ T cells have impaired interleukin-10 production which is not restored by probiotic bacteria | Q63727331 | ||
| The obligate anaerobic faecal flora of patients with Crohn's disease and their first-degree relatives | Q68070823 | ||
| Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) | Q70823350 | ||
| Dietary supplement of neosugar alters the fecal flora and decreases activities of some reductive enzymes in human subjects | Q71043706 | ||
| Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus | Q72737230 | ||
| The GI core curriculum: five years later | Q73838415 | ||
| Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial | Q79510185 | ||
| Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome | Q80701381 | ||
| Significance of the discovery of the effects of cortisone on rheumatoid arthritis | Q80756566 | ||
| Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota | Q81402999 | ||
| Different effects of probiotic species/strains on infections in preschool children: A double-blind, randomized, controlled study | Q83121425 | ||
| Probiotics as adjunctive treatment for chronic rhinosinusitis: a randomized controlled trial | Q83313170 | ||
| A mixture of Lactobacillus plantarum CECT 7315 and CECT 7316 enhances systemic immunity in elderly subjects. A dose-response, double-blind, placebo-controlled, randomized pilot trial | Q83967220 | ||
| Effect of 25 weeks probiotic supplementation on immune function of HIV patients | Q84260842 | ||
| Honor thy symbionts | Q28202174 | ||
| Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial | Q28211907 | ||
| Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis | Q28258829 | ||
| Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study | Q28271581 | ||
| Probiotics, prebiotics, and synbiotics | Q28279222 | ||
| Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study | Q28281530 | ||
| Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial | Q28287413 | ||
| Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial | Q28290635 | ||
| A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing Lactobacillus casei in pre-school children with allergic asthma and/or rhinitis | Q28307749 | ||
| Evolution of mammals and their gut microbes | Q28755326 | ||
| The hygiene hypothesis: an evolutionary perspective | Q29301132 | ||
| Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns | Q29547261 | ||
| Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis | Q29547656 | ||
| A microbial symbiosis factor prevents intestinal inflammatory disease | Q29614263 | ||
| An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system | Q29614267 | ||
| The effect of infections on susceptibility to autoimmune and allergic diseases | Q29618525 | ||
| Effect of the consumption of a fermented dairy product containing Bifidobacterium lactis DN-173 010 on constipation in childhood: a multicentre randomised controlled trial (NTRTC: 1571). | Q33419501 | ||
| A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics | Q33425717 | ||
| Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study | Q33426019 | ||
| The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study | Q33433775 | ||
| A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. | Q33433931 | ||
| A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating | Q33434046 | ||
| Systematic review of randomised controlled trials: probiotics for functional constipation | Q33521058 | ||
| Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases | Q33691828 | ||
| Use of probiotics for prevention of radiation-induced diarrhea | Q33787744 | ||
| Probiotics in infective diarrhoea and inflammatory bowel diseases. | Q33939743 | ||
| A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome | Q33955996 | ||
| Helicobacter pylori and probiotics | Q34002541 | ||
| A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome | Q34010853 | ||
| The immune system and the gut microbiota: friends or foes? | Q34024073 | ||
| Immune adaptations that maintain homeostasis with the intestinal microbiota | Q34100501 | ||
| Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children | Q34110147 | ||
| Probiotics for prevention and treatment of diarrhea. | Q34223539 | ||
| Beneficial health effects of low-digestible carbohydrate consumption | Q34230596 | ||
| Health benefits of probiotics: are mixtures more effective than single strains? | Q37828084 | ||
| Evidence supporting the use of probiotics for the prevention and treatment of chemotherapy-induced intestinal mucositis | Q37851431 | ||
| An evidence-based systematic review on medical therapies for inflammatory bowel disease | Q37862584 | ||
| Clinical utility of probiotics in inflammatory bowel disease | Q37880028 | ||
| Inflamed gut mucosa: downstream of interleukin-10. | Q37883443 | ||
| Regulatory B-cell induction by helminths: implications for allergic disease | Q37891519 | ||
| Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection | Q37892873 | ||
| Probiotics and prebiotics in periodontal therapy | Q37926403 | ||
| Gut Microbiota and Inflammatory Bowel Disease | Q37969587 | ||
| Host-recognition of pathogens and commensals in the mammalian intestine | Q37969599 | ||
| The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial | Q39254792 | ||
| Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution | Q34440722 | ||
| Maternal antibodies, childhood infections, and autoimmune diseases | Q34495968 | ||
| Probiotics in man and animals | Q34505006 | ||
| Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial | Q34510060 | ||
| Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. | Q34540585 | ||
| Prebiotics and synbiotics in clinical medicine | Q34561563 | ||
| The germless theory of allergic disease: revisiting the hygiene hypothesis. | Q34572144 | ||
| The enteric microbiota in the pathogenesis and management of constipation | Q34627399 | ||
| Probiotics and oral health effects in children | Q34726463 | ||
| Probiotics: a novel approach in the management of food allergy | Q34738168 | ||
| Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial. | Q34768241 | ||
| Irritable bowel syndrome, gut microbiota and probiotics. | Q35161373 | ||
| Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis | Q35596222 | ||
| T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated immunopathology in Crohn's disease. | Q35596780 | ||
| Bacterial contributions to mammalian gut development | Q35682785 | ||
| Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease | Q35760252 | ||
| The tight junction: a multifunctional complex | Q35777543 | ||
| Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women | Q35956919 | ||
| Is Lactobacillus rhamnosus GG effective in preventing the onset of antibiotic-associated diarrhoea: a systematic review | Q36237066 | ||
| How Toll-like receptors signal: what we know and what we don't know | Q36339101 | ||
| Sensor molecules in intestinal innate immunity against bacterial infections | Q36388846 | ||
| Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take "toll" ? | Q36446276 | ||
| Regulation of regulatory T cells: role of dendritic cells and toll-like receptors | Q36638378 | ||
| Probiotics and prebiotics: effects on diarrhea | Q36740872 | ||
| Prebiotics, probiotics, and synbiotics affect mineral absorption, bone mineral content, and bone structure | Q36740890 | ||
| Probiotic bacteria: legislative framework-- requirements to evidence basis | Q36740898 | ||
| Healthy aging: regulation of the metabolome by cellular redox modulation and prooxidant signaling systems: the essential roles of superoxide anion and hydrogen peroxide | Q36784445 | ||
| The physiological relevance of the intestinal microbiota--contributions to human health | Q37054663 | ||
| Probiotics for the treatment or prevention of atopic dermatitis: a review of the evidence from randomized controlled trials | Q37088384 | ||
| Effect of supplement with lactic-acid producing bacteria on fatigue and physical activity in patients with chronic fatigue syndrome | Q37097581 | ||
| Probiotics in the treatment of human inflammatory bowel diseases: update 2008. | Q37187326 | ||
| The use of probiotics in the prevention and treatment of antibiotic-associated diarrhea with special interest in Clostridium difficile-associated diarrhea | Q37401586 | ||
| Probiotics, immune function, infection and inflammation: a review of the evidence from studies conducted in humans | Q37481930 | ||
| Helicobacter pylori infection and childhood | Q37807483 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prebiotics | Q218870 |
| immune tolerance | Q1356761 | ||
| probiotics | Q1816730 | ||
| P304 | page(s) | 251-266 | |
| P577 | publication date | 2012-03-18 | |
| P1433 | published in | Inflammopharmacology | Q15751310 |
| P1476 | title | A review of the pharmacobiotic regulation of gastrointestinal inflammation by probiotics, commensal bacteria and prebiotics | |
| P478 | volume | 20 |
| Q47706915 | Anti-arthritic activity of cell wall content of Lactobacillus plantarum in freund's adjuvant-induced arthritic rats: involvement of cellular inflammatory mediators and other biomarkers |
| Q38966092 | Four types of Bifidobacteria trigger autophagy response in intestinal epithelial cells |
| Q37357860 | From the gastrointestinal tract (GIT) to the kidneys: live bacterial cultures (probiotics) mediating reductions of uremic toxin levels via free radical signaling |
| Q35805066 | Gastrointestinal Tract Commensal Bacteria and Probiotics: Influence on End-Organ Physiology |
| Q36325163 | Ginger-derived nanoparticles protect against alcohol-induced liver damage |
| Q44590836 | Green-lipped mussel extract (Perna canaliculus) and glucosamine sulphate in patients with knee osteoarthritis: therapeutic efficacy and effects on gastrointestinal microbiota profiles |
| Q34342016 | Live probiotic cultures and the gastrointestinal tract: symbiotic preservation of tolerance whilst attenuating pathogenicity |
| Q42213232 | Observation of inflammatory responses in mice orally fed with bacteriophage T7. |
| Q39024657 | Probiotics, D-Lactic acidosis, oxidative stress and strain specificity |
| Q35122167 | Probiotics, prebiotics and the gastrointestinal tract in health and disease |
| Q41984412 | The gastrointestinal microbiome and musculoskeletal diseases: a beneficial role for probiotics and prebiotics |
| Q35286036 | The gastrointestinal tract microbiome, probiotics, and mood |
| Q34309689 | The overarching influence of the gut microbiome on end-organ function: the role of live probiotic cultures |
| Q34602194 | Uremia and chronic kidney disease: The role of the gut microflora and therapies with pro- and prebiotics |
Search more.